Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Zydus Lifesciences Limited currently has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct examiners, showing that each active application is being reviewed by a different individual. The portfolio spans 4 distinct art units, which indicates that the company's filings are classified under several different technical groups at the USPTO.
The busiest examiner for this portfolio is OH, TAYLOR V, who is currently handling 1 pending office action. As the 4 pending office actions are spread among 4 distinct examiners, no single individual dominates the prosecution landscape. This distribution requires the company to manage four different examiner styles within the Biotechnology & Pharmaceuticals sector.
Managing 4 pending office actions across 4 distinct art units requires a strategy that can accommodate different technical standards. Because OH, TAYLOR V handles 1 pending office action, the company's success is distributed across the decisions of all 4 distinct examiners. This variety ensures that the portfolio's progress is not overly dependent on the discretion of any one official.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OH, TAYLOR V | 1 | 81.2% | +15.3% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| KWON, JOHN SEUNGJAI | 1 | 45.7% | +19.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19434846 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RADIATION INDUCED TOXICITY | OH, TAYLOR V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293826 | STABLE PHARMACEUTICAL COMPOSITIONS OF APOMORPHINE | ATKINSON, JOSHUA ALEXANDER | 73d overdue |
| 19434846 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RADIATION INDUCED TOXICITY | OH, TAYLOR V | — |
| 18325249 | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF COPPER HISTIDINATE | KWON, JOHN SEUNGJAI | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1612 | 1 |
| 1617 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19434846 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RADIATION INDUCED TOXICITY | OH, TAYLOR V | 1625 | §103 | Final Rejection | — | Pending | Dec 29, 2025 |
| 18293826 | STABLE PHARMACEUTICAL COMPOSITIONS OF APOMORPHINE | ATKINSON, JOSHUA ALEXANDER | 1612 | §103 | Final Rejection | 73d overdue | Pending | Jan 31, 2024 |
| 18578843 | PHARMACEUTICAL COMPOSITIONS OF OZANIMOD | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Final Rejection | 30d overdue | Pending | Jan 12, 2024 |
| 18325249 | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF COPPER HISTIDINATE | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | — | Pending | May 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial